Risk sharing agreements have been a strategic tool employed for more than a decade. Yet, they’re still widely misunderstood — and underutilized, especially as they may help provide access to a frugal, risk-averse marketplace.
Are you up to speed on all that a risk sharing agreement might do for your product or organization?
Payer Perspectives on Risk Sharing offers expert insights on how risk sharing agreements can be a win-win for both pharmaceutical companies and payers in helping to build relationships and achieve optimal market access. In addition, gain perspective on when and how the right risk sharing agreement can help your product succeed in the marketplace.
Answers to Critical Questions
Filled with charts and up-to-the-minute survey analysis, this report offers:
About FirstWord Reports
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
Table of Contents
for Payer Perspectives on Risk Sharing Deals [Published by FirstWord Pharma]
2.Research objectives and methodology
3.Setting the scene
3.2.Austerity remains a watchword for payers
3.3.Rising cost of new medicines and uncertainty in their real value
3.4.Protecting list prices
3.5.Rise in Health Technology Assessment and the rise in risk sharing
3.6.Matching the increasing flexibility from the European regulator in 2015
3.7.Risk sharing schemes can provide a ‘third way’ to provide patient access
4.Risk sharing schemes in the 2000s
and 2010s – managed access by another name
4.2.The many names for risk sharing schemes
4.3.Increasing popularity of schemes but still a niche
4.5.Different risks, different schemes
4.6.Learning by doing: past experience can guide choice of scheme in
5.Risk sharing schemes are an important part of the market access
jigsaw in Europe and the US in 2015
5.2.France – limited use of performance-based risk sharing, widespread use of
financial-based risk sharing
5.2.1.A handful of examples of performance-based risk sharing
5.2.2.Risk sharing in France is shorthand for performance-based schemes
5.2.3.Performance-based risk sharing schemes are not a substitute for poor clinicaldevelopment
5.2.4.Performance-based risk sharing schemes can be explored early by companies
5.2.5.Companies should take a tailored approach to deciding on outcomes and data
needed for schemes
5.2.6.Offering a performance-based risk sharing scheme is a strategic choice and
comes with risk for the manufacturer
5.3.Germany – not open to risk sharing schemes
5.4.Italy – a trail blazer for risk sharing schemes
5.4.1.More schemes than any other country
5.4.2.Risk sharing is just one of three types of schemes in Italy
5.4.3.A shift towards performance-based schemes but AIFA is focused on what
makes sense in context
5.4.4.AIFA is driving the adoption of schemes
5.4.5.Schemes provide access that would not otherwise be available,
but with the risk of lower prices and paybacks in future
5.5.Spain – a patchwork of national and regional schemes
5.5.1.Limited number of national schemes, and the regions are leading the way
5.5.2.Payers want schemes that are performance related
5.5.3 Companies should engage early when thinking about developing
a risk sharing scheme
5.5.4.Outcomes and data should reflect the context and make use of existing
infrastructure, where it is available
5.5.5.Companies can take up opportunities to work with Health Technology
Assessment Agencies to develop schemes
5.5.6.Improve access with schemes, without necessarily reducing your price
5.6.UK – from complex schemes to simple schemes
5.6.1.A pioneer in risk sharing since 2002
5.6.2.From risk sharing to Patient Access Schemes
5.6.3.Emphasis on simple schemes
5.6.4.Outcome-based schemes may come in the future
5.6.5.Engage early with the NHS
5.6.6.What data do payers want to support risk sharing schemes?
5.6.7.Simple schemes mitigate against the need to collect data
5.6.8.Just ask for help if you are thinking of putting forward a scheme
5.6.9.Protection of list price whilst securing access
5.7.US – early experimentation and renewed interest in 2015
5.7.1.Public and private payers have adopted risk sharing schemes in the past
5.7.2.Payers are concerned that the only winners from risk sharing schemes are
5.7.3.Payers want ‘true’ risk sharing schemes
5.7.4.More proposals for schemes are expected by payers
5.7.5.Companies will have to keep their proposals for schemes simple if they
want Payers to seriously consider them
5.7.7.Measure outcomes that matter in context, and explore guaranteeing
your product can avoid costly care
5.7.8.Potential to improve
|Title||Date Published||Price from||More Details|
|Cancer Immunotherapy: Payer Insight|
IntroductionImmunotherapies are some of the most promising new weapons in the fight against cancer. ...
|01 Oct 2015 by FirstWord Pharma||USD $7,900||More Info|
|Biosimilars: US Payer Perspectives|
IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
|01 Apr 2015 by FirstWord Pharma||USD $2,195||More Info|
|Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectives|
IntroductionIt all started years ago, with a few patients asking questions on the internet. These da...
|01 Apr 2015 by FirstWord Pharma||USD $695||More Info|
|Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?|
Scope Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight t...
|25 Feb 2015 by FirstWord Pharma||USD $695||More Info|
|Biosimilars: European Payer Perspectives|
IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
|06 Jan 2015 by FirstWord Pharma||USD $2,195||More Info|
|Orphan Drug Market Access: Payer Insights on the Present and Future|
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
|14 Oct 2014 by FirstWord Pharma||USD $695||More Info|
|Patient Assistance Programs: Payer and Pharma Perspectives|
IntroductionPatient assistance programs (PAPs) are evolving in response to increasingly restrictive ...
|02 Oct 2014 by FirstWord Pharma||USD $695||More Info|
|Payer Insights: Hepatitis C|
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
|26 Sep 2014 by FirstWord Pharma||USD $7,900||More Info|
|Oncology Market Access Europe – Payer and Industry Perspectives|
IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
|03 Jul 2014 by FirstWord Pharma||USD $995||More Info|
|Pharma and the Changing US Payer Environment: Meeting the demands of Accountable Care Organizations (ACOs)|
IntroductionThere’s a revolution happening...and it’s going to change the way pharma thinks. As the ...
|01 Nov 2013 by FirstWord Pharma||USD $695||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.